The clinical classification of patients with AHF continues to evolve, and reflects ongoing changes in the understanding of the pathophysiology of the Paclitaxel syndrome [3-5]. AHF outcomes remain poor. Prevalence of in-hospital mortality as high as 10% and prevalence of re-hospitalization >50% within 1 year have been reported [6,7]. In the prospective cohort of hospitalized patients with AHF (ADHERE), in-hospital mortality was 4% [8]; the Second EuroHeart Failure Survey (EHFS II) had an in-hospital mortality of 6.7% [1].Despite the magnitude of the burden of AHF and the intense interest in this dire problem, effective new therapies capable of reducing the prevalence of early mortality or re-hospitalization have not been developed over the past decade [7]. The etiology of AHF is mainly ischemic heart disease (IHD) [9].

Invasive methods in cardiology have significantly expanded in recent years.The aim of this work is to describe a large population of patients hospitalized for syndromes of AHF, their in-patient therapy and mortality and to assess major risk factors of adverse short term prognosis in terms of frequently used invasive and therapeutic methods. The patients with AHF were systematically sorted according to AHF guidelines [3].Materials and methodsStudy populationsThe Acute Heart Failure Database (AHEAD) registry consists of two independent parts. The AHEAD main registry includes consecutive patients in seven centers with a 24-hour Catheterization Laboratory service and centralized care for patients with acute coronary syndromes (ACS) from a region of about three million inhabitants.

The AHEAD network also includes five regional hospitals without a Catheterization Laboratory service. The present work includes only patients from Dacomitinib the AHEAD main registry.The inclusion criteria for the database adhere to the European guidelines for AHF. Hence, there must be the signs and symptoms of HF, confirmed left-ventricular dysfunction (systolic or diastolic) and/or positive response to therapy [3]. The decision on inclusion in the registry and filling the database were done by responsible cardiologists. There was no exclusion criterion.